Literature DB >> 11569943

Pathogenesis of Parkinson's disease.

T B Sherer1, R Betarbet, J T Greenamyre.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by degeneration of the nigrostriatal dopaminergic pathway and the appearance of cytoplasmic proteinaceous aggregates known as Lewy bodies. Studies of familial PD have uncovered rare causative mutations in genes, including alpha-synuclein. Mutations or oxidative modification of alpha-synuclein causes it to aggregate; alpha-synuclein is a major component of the Lewy body in both familial and sporadic PD. Biochemical analysis has implicated mitochondrial dysfunction in PD. Epidemiological studies indicate a role of exposure to pesticides, some of which are mitochondrial toxins. Mitochondrial dysfunction, resulting from genetic defects, environmental toxins, or a combination of the two, may cause alpha-synuclein aggregation and produce selective neurodegeneration through mechanisms involving oxidative stress and excitotoxicity. Efforts to better define PD pathogenesis should reveal novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11569943

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  32 in total

1.  Next-generation sequencing reveals regional differences of the α-synuclein methylation state independent of Lewy body disease.

Authors:  L de Boni; S Tierling; S Roeber; J Walter; A Giese; Hans A Kretzschmar
Journal:  Neuromolecular Med       Date:  2011-11-01       Impact factor: 3.843

2.  Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.

Authors:  Mark Johnson; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2012-06-13       Impact factor: 7.446

Review 3.  Cannabinoids and neuroprotection in basal ganglia disorders.

Authors:  Onintza Sagredo; Moisés García-Arencibia; Eva de Lago; Simone Finetti; Alessandra Decio; Javier Fernández-Ruiz
Journal:  Mol Neurobiol       Date:  2007-06-23       Impact factor: 5.590

4.  Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels.

Authors:  Eldo V Kuzhikandathil; Samantha Cote; Soumava Santra; Aloke K Dutta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-20       Impact factor: 3.000

5.  Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.

Authors:  Sanjib Gogoi; Tamara Antonio; Subramanian Rajagopalan; Maarten Reith; Julie Andersen; Aloke K Dutta
Journal:  ChemMedChem       Date:  2011-05-12       Impact factor: 3.466

6.  Investigation of Long Non-coding RNA Expression Profiles in the Substantia Nigra of Parkinson's Disease.

Authors:  Yaohui Ni; Hua Huang; Yaqin Chen; Maohong Cao; Hongzhi Zhou; Yuanyuan Zhang
Journal:  Cell Mol Neurobiol       Date:  2016-05-05       Impact factor: 5.046

7.  [Primary open-angle glaucoma and systemic diseases].

Authors:  M Pache
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

8.  Rosmarinic acid inhibits 6-OHDA-induced neurotoxicity by anti-oxidation in MES23.5 cells.

Authors:  Pei Ren; Hong Jiang; Ronggui Li; Jun Wang; Ning Song; Hua-Min Xu; Jun-Xia Xie
Journal:  J Mol Neurosci       Date:  2009-02-14       Impact factor: 3.444

9.  Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.

Authors:  Gyan Modi; Chandrashekhar Voshavar; Sanjib Gogoi; Mrudang Shah; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Chem Neurosci       Date:  2014-07-09       Impact factor: 4.418

Review 10.  G proteins, p60TRP, and neurodegenerative diseases.

Authors:  Klaus Heese
Journal:  Mol Neurobiol       Date:  2013-01-24       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.